Cargando…

Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease

INTRODUCTION: Warfarin remains the preferred oral anticoagulant for the treatment of venous thromboembolism (VTE) in patients with advanced chronic kidney disease (CKD). Although the direct oral anticoagulants (DOACs) have become preferred for treatment of VTE in the general population, patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahuja, Tania, Sessa, Kelly, Merchan, Cristian, Papadopoulos, John, Green, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895609/ https://www.ncbi.nlm.nih.gov/pubmed/33628255 http://dx.doi.org/10.1155/2021/8870015

Ejemplares similares

The role of factor Xa inhibitors in venous thromboembolism treatment
por: Cabral, Katherine P, et al.
Publicado: (2015)

Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery
por: Kushnir, Margarita, et al.
Publicado: (2022)

Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency
por: Minami, Kentaro, et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
por: Cohen, Alexander T., et al.
Publicado: (2021)

Comparative analysis and meta-analysis of major clinical trials with oral factor Xa inhibitors versus warfarin in atrial fibrillation
por: Nunes, José Pedro L, et al.
Publicado: (2014)

Warfarin versus factor Xa inhibitors in the long-term treatment of cerebral venous sinus thrombosis a single-center retrospective analysis
por: Christodoulides, Alexei, et al.
Publicado: (2022)

Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2021)

Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism
por: Kang, Hye‐Rim, et al.
Publicado: (2023)

Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis
por: Nugroho Eko Putranto, Johanes, et al.
Publicado: (2021)

Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis
por: Park, Dae Yong, et al.
Publicado: (2023)

Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding
por: Rech, Megan A., et al.
Publicado: (2021)

Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
por: Lutsey, Pamela L., et al.
Publicado: (2019)

Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2023)

742 Evaluation of Anti-Xa Levels and Venous Thromboembolism Prophylaxis with Enoxaparin in Burn Patients
por: Boyd, Allison, et al.
Publicado: (2023)

Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism
por: Witt, Daniel M., et al.
Publicado: (2016)

Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism
por: Vandell, Alexander G, et al.
Publicado: (2017)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Therapeutic options for the treatment of venous thromboembolism in case of warfarin intolerance: Effects of novel oral anticoagulants
por: Kodani, Eitaro
Publicado: (2013)

Venous thromboembolic prophylaxis after simultaneous bilateral total knee arthroplasty: aspirin versus warfarin
por: Goel, R., et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
por: Weycker, Derek, et al.
Publicado: (2018)

Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban—an oral, direct Factor Xa inhibitor
por: Burghaus, Rolf, et al.
Publicado: (2014)

Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end‐stage kidney disease: A national cohort study
por: Ellenbogen, Michael I., et al.
Publicado: (2022)

Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study
por: Jun, Min, et al.
Publicado: (2017)

Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
por: Weycker, Derek, et al.
Publicado: (2018)

Direct oral anti-Xa anticoagulants versus warfarin in newly diagnosed atrial fibrillation and CKD: the Korean National Health Insurance Data
por: Kee, Youn Kyung, et al.
Publicado: (2023)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson, Pontus B
Publicado: (2015)

Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients
por: Al Otaib, Nouf, et al.
Publicado: (2017)

Value of venous thromboembolism prophylaxis by enoxaparin with anti-factor Xa trough concentration monitoring in surgical care
por: Zachariah, Seeba, et al.
Publicado: (2020)

Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
por: Mavromanoli, Anna C., et al.
Publicado: (2021)

The Safety of Direct Oral Anticoagulants Versus Warfarin Among Older Individuals With Acute Venous Thromboembolism and CKD: A Population-Based Cohort Study
por: Harel, Ziv, et al.
Publicado: (2022)

Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis
por: Niyomsri, Siwaporn, et al.
Publicado: (2023)

Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status
por: Cohen, Alexander T., et al.
Publicado: (2021)

Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis
por: Liu, Zhuang, et al.
Publicado: (2023)

Evaluation of anti-Xa levels in patients with venous thromboembolism within the first 48 h of anticoagulation with unfractionated heparin
por: Nguyen, Lily, et al.
Publicado: (2023)

Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis
por: Costa, Olivia S., et al.
Publicado: (2020)

Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis
por: Zakai, Neil A., et al.
Publicado: (2021)

Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK
por: Clay, Emilie, et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
por: Cohen, Alexander, et al.
Publicado: (2021)

Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network
por: Ruigómez, Ana, et al.
Publicado: (2020)

Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding
por: Kang, Hye-Rim, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aun377h5s5ni6303pnbr7p6pit